Cognosci

Website Links

Description

MS is a chronic, unpredictable neurological disease that affects the central nervous system. It is thought to be an autoimmune disorder, meaning the immune system incorrectly attacks healthy tissue. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. These problems may be permanent or may come and go.

Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for treatment of neuroinflammatory diseases such as Multiple Sclerosis, Alzheimer's Disease, intracranial hemorrhage, and Traumatic Brain Injuries. Each of these disorders has a pharmacogenomic linkage to the apolipoprotein-E gene. Cognosci's platform for identification of compounds to treat these disorders has produced compounds that are efficacious in animal models of each of these disease indications.

Dr. O'Connor has a vast experience with the clinical aspects of MS and directs one of the largest and most clinically active MS centers in the world. Along with providing leadership to the clinic service and research staff, he runs a very busy MS practice and evoked potential diagnostic facility. He received his MD and MSc degree from the University of Toronto and was made a Fellow of the Royal College of Physicians and Surgeons of Canada in Neurology in 1985.

Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for the treatment of neuroinflammatory diseases including Multiple Sclerosis, Alzheimer's Disease, and brain bleeding events. Each of these disorders has a pharmacogenomic linkage to the apolipoprotein E (APOE) protein and patients with the APOE-?4 allele typically suffer worse outcomes. Based on these findings, scientists from Duke University created a novel APOE-based compound that had potent anti-inflammatory and neuroprotective activities.

Fact sheet

Company contacts

Products & services

Similar companies nearby